DIAGNOSTIC SOLUTIONS & HEALTHCARE CHALLENGES

AST / MIC / Resistance Testing

The global incidence of multi-drug resistance (MDR) among gram-negative and gram-positive pathogens has risen in recent years, with serious consequences for both hospital- and community-acquired infections.

AST / MIC / Resistance Testing

Detecting the potential resistance mechanisms and phenotypic resistance of organisms with high mortality rates such as Enterococcus fae­cium, Staphylococcus aureus, Klebsiella pneu­moniae, Acinetobacter baumannii, Pseudomonas aeruginosa, Enterobacter spp. and Escherichia coli is of high clinical and epidemiological importance.

Bruker offers a meaningful portfolio of MALDI-TOF based, broth microdilution and molecular assays to detect antimicrobial resistance determinants and phenotypic resistance to critically important antibiotics.

MALDI-TOF mass spectrometry has the potential to identify specific resistance markers. When using the IVD MALDI Biotyper® the dedicated MBT Subtyping® IVD Module combines the identification of important pathogens with automated subsequent detection of specific resistance markers in one automated workflow, providing a warning about a potential resistance.

With the subsequent MBT-STAR® IVD assays, the IVD MALDI Biotyper® combines microbial identification with phenotypic detection of carbapenemase and cephalosporinase activity.

With the negative ion mode available on Bruker’s high-end MALDI Biotyper® sirius Systems, analysis of lipids has become accessible for microbial research, enabling exploration of lipidomics for resistance detection. The MBT Lipid XtractTM Kit (RUO) allows sample preparation of the Lipid A molecule and all its modifications within less than 15 minutes and therefore delivering rapid colistin resistance detection.

The MICRONAUT and UMIC® broth microdilution (BMD) assays provide specialty and routine antimicrobial and antifungal susceptibility testing solutions as well as convenient and flexible MIC determination of highest accuracy for single antibiotics (UMIC®) like colistin, cefiderocol, and piperacillin-tazobactam.

Bruker further supports resistance management by offering the Carbaplex® real-time PCR kit to detect presence of the big 5 carbapenemase genes from a rectal swab, for patients who are at risk of colonization from Carbapenamase Producing Enterobacteriaceae (CPE).